Drug detection times and cut-off levels answer different questions. A detection window describes how long a particular drug or marker may remain detectable in a sample. A cut-off is the threshold used by a particular test to classify its screening response. Understanding both helps you compare kits without mistaking a result for a complete account of someone’s drug use.
This guide explains ng/mL, gives a qualified urine detection reference, and compares the cut-offs published for VivaTest urine and saliva tests. For sample collection and result diagrams, read our urine versus saliva drug testing guide. To compare the whole range, use our guide to choosing a drug test.
What does ng/mL mean on a drug test?
ng/mL means nanograms per millilitre: a unit of concentration. One nanogram is one billionth of a gram. The number printed beside a drug label describes the kit’s stated cut-off for a target in the specified sample; it is not the amount someone took.
For example, “THC 50 ng/mL” and “THC 20 ng/mL” describe different stated thresholds. To compare them meaningfully, you also need to know the sample type and the chemical target. A urine metabolite threshold and an oral-fluid threshold cannot be treated as interchangeable measurements.
A qualitative rapid screen gives a category, not a measured concentration. The printed cut-off is not a sample’s numerical result. Discuss laboratory testing if a measurement is needed. 1
How is a cut-off different from a detection window?
| Term | What it describes | What it does not establish |
|---|---|---|
| Cut-off | A test’s stated classification threshold for a target and sample type | A safe dose or a universal legal limit |
| Detection window | An estimated period during which a marker may be detected | A guaranteed result on a particular day |
| Reading time | When to interpret the device after starting it | How long the drug stays in the body |
| Panel count | The labelled screening parameters on a device | The number of tests in a pack |
Detection varies with the substance, dose and frequency of exposure, individual metabolism, sample quality and the assay’s design. The body’s clearance of a substance and the point at which one device stops detecting it are related, but they are not the same measurement. 2
Drug detection times in urine: a reference table
These estimates come from ARUP Laboratories’ October 2023 reference. They describe urine testing generally, not validated detection periods for individual VivaTest devices. Different assays and cut-offs can produce different results. 3
| Substance or urine marker | Reference urine window | Context |
|---|---|---|
| Amphetamine | 1–5 days | Substance-specific estimate |
| Methamphetamine | 1–5 days | Substance-specific estimate |
| Cocaine metabolite, benzoylecgonine | 1–2 days | Metabolite rather than parent cocaine |
| MDMA | 1–3 days | Separate screening target |
| THC metabolite | 1–45 days | Particularly broad estimate |
| Codeine | 1–3 days | Relevant to opiate interpretation |
| Morphine | 1–3 days | Relevant to opiate interpretation |
| Heroin metabolite, 6-MAM | Less than 1 day | Shorter window than some other opiate markers |
| Oxycodone | 1–3 days | Separate target may be needed |
| Fentanyl / norfentanyl | 1–3 days | Depends on the assay target |
| Methadone / EDDP | 1–14 days | Depends on the assay target |
| Alprazolam | 1–4 days | Benzodiazepines differ |
| Diazepam | 1–7 days | Benzodiazepines differ |
| Tramadol | 1–4 days | Parent-drug reference |
The widest range is not a prediction for every person. These figures should not be used to calculate a date when a result must become negative. Nor should a single result be used to reconstruct the exact date or amount of an exposure.
Why is there no single benzodiazepine detection time?
Benzodiazepines form a drug class. Metabolism and assay responses differ, so a BZO panel may not detect each medicine equally well. Check the leaflet’s reactivity information. 2
How long do drugs remain detectable in saliva?
Oral-fluid testing generally covers a more recent period than urine testing. SAMHSA’s programme comparison describes oral-fluid windows ranging from minutes to around two days, depending on the drug. This is background context, not a promised window for a VivaTest kit. 4
Use the exact device’s leaflet for its validated claims. Avoid treating “24 hours”, “48 hours” or “72 hours” as a rule covering every oral-fluid target. A longer or shorter window is only useful if it matches the question you are trying to answer.
VivaTest urine drug test cut-off levels
The table below reproduces the named-target cut-offs published on the linked product pages, checked on 9 October 2026. All numerical entries are in ng/mL. A dash means the target is not listed for that product; it does not mean a zero cut-off. Confirm specifications against the leaflet supplied with your device.
| Published target / label | 3-panel urine | 8-panel urine | 22-panel urine cup |
|---|---|---|---|
| Amphetamine — AMP | 1000 | 1000 | 1000 |
| Barbiturates — BAR | — | — | 300 |
| Benzodiazepines — BZO | — | 300 | 300 |
| Buprenorphine — BUP | — | — | 10 |
| Cocaine — COC | 300 | 300 | 300 |
| Methamphetamine — MET | — | 1000 | 1000 |
| MDMA | — | 500 | 500 |
| Methadone — MTD | — | 300 | 300 |
| Morphine / opiate — MOP | — | — | 300 |
| Opiates — OPI | — | 2000 | 2000 |
| Oxycodone — OXY | — | — | 100 |
| Phencyclidine — PCP | — | — | 25 |
| Propoxyphene — PPX | — | — | 300 |
| Tricyclic antidepressants — TCA | — | — | 1000 |
| Cannabis — THC | 50 | 50 | 50 |
| Tramadol — TML | — | — | 1000 |
| Ethyl glucuronide — EtG | — | — | 500 |
| Cotinine — COT | — | — | 200 |
| Heroin metabolite — 6-MAM | — | — | 10 |
| Ketamine — KET | — | — | 1000 |
| Fentanyl — FYL | — | — | 10 |
The 22-panel listing also includes “NIT”, without identifying its full target in the published description. Its name and interpretation should be confirmed from the supplied leaflet before relying on that parameter. It is not expanded into a drug name in this guide.
For single-target screening, the THC urine drug test, 50 ng/mL and Cocaine urine drug test, 300 ng/mL publish the same respective thresholds as the THC and COC panels shown above. A single-target result does not cover the other substances in the table.
VivaTest saliva drug test cut-off levels
These are the oral-fluid cut-offs published on the linked product pages, also in ng/mL. The 16-panel kit has its own specification: the figures for the smaller saliva kits should not be applied to it.
| Published target / label | 3-panel saliva | 6-panel saliva | 16-panel saliva |
|---|---|---|---|
| Amphetamine — AMP | — | 50 | 50 |
| Methamphetamine — MET | — | 25 | 50 |
| Cannabis — THC | 20 | 20 | 12 |
| Phencyclidine — PCP | — | — | 10 |
| Cocaine — COC | 20 | 20 | 20 |
| Opiates — OPI | 10 | 10 | 40 |
| Methadone — MTD | — | — | 30 |
| MDMA | — | — | 50 |
| Oxycodone — OXY | — | — | 20 |
| Benzodiazepines — BZO | — | 20 | 30 |
| Ketamine — KET | — | — | 50 |
| Barbiturates — BAR | — | — | 50 |
| Buprenorphine — BUP | — | — | 10 |
| Tramadol — TML | — | — | 30 |
| Fentanyl — FYL | — | — | 20 |
| Propoxyphene — PPX | — | — | 50 |
For example, the published THC cut-off is 20 ng/mL for the 3- and 6-panel saliva devices, compared with 12 ng/mL for the 16-panel device. That difference does not establish how many additional hours a substance will remain detectable.
What do EtG and cotinine results mean?
EtG is an alcohol metabolite. An EtG result concerns a marker of alcohol exposure; it is not a breath-alcohol reading or a measure of current intoxication. Clinical EtG results do not reliably establish the amount or frequency of drinking. 5
Cotinine is a nicotine metabolite. Nicotine exposure can come from tobacco, nicotine-containing vaping products or nicotine replacement therapy. A cotinine screen alone does not identify which source was used. 6
Is a lower cut-off always better?
A lower number can change classification near a threshold, but it does not make every aspect of a test better. Compare the same target, sample type and intended purpose first. More extensive coverage and a lower threshold are different product features.
Near a cut-off, devices may give different screening responses. Line strength does not measure concentration. For uncertain results or important decisions, arrange appropriate laboratory confirmation. 7
Can detection times show whether someone is safe to drive?
A home urine or saliva screen cannot establish that someone is safe or legally permitted to drive. Drug-driving law concerns impairment and, for specified substances, blood limits; these are not interchangeable with a kit’s urine or oral-fluid cut-offs. Ask a doctor or pharmacist about medicines and driving. 8
Frequently asked questions
Does a negative screen mean there is no drug in the body?
No. A negative screening response can occur when a target is below that test’s cut-off or outside its detection window. The result also only covers the targets included on the device. It should not be described as an “all drugs clear” result. 9
Can a rapid test tell me the exact ng/mL result?
No. The cut-off printed on a qualitative kit is a specification, not a concentration readout. If a measured concentration is needed, discuss an appropriate laboratory test and interpretation with a professional.
Does an OPI result identify every opioid?
No. Standard opiate immunoassays may miss synthetic opioids and some semisynthetic opioids. Separate targets such as FYL, OXY, MTD or BUP may be needed. Match the named substance to the actual panel rather than assuming “opiates” covers the whole opioid family. 2
Should I rely on a second rapid test to confirm a positive?
A repeat rapid screen remains a screen. It does not become definitive confirmation simply because the same result appears twice. Our guide to urine and saliva testing explains the difference between screening and laboratory follow-up.
Explore the next guide
Read urine versus saliva drug testing for practical sample and result guidance, or how to choose the right drug test for a full product comparison. Return to Drug Testing Resources or browse all VivaTest drug tests.
Sources and product information checked: 9 October 2026. General references explain testing principles; they do not validate the performance, approval status or instructions of an individual VivaTest device.
Sources and further reading
- FDA: Drugs of abuse home-use tests — general screening guidance
- ARUP Consult: Drug testing
- ARUP Laboratories: Drug plasma half-life and urine detection window, October 2023
- SAMHSA: Overview of urine and oral fluid drug testing — US programme comparison
- ARUP Consult: Alcohol use biomarkers
- ARUP Consult: Nicotine exposure and metabolites
- Abbott Toxicology: Rapid screening and result interpretation FAQs
- GOV.UK: Drugs and driving
- ASAM: Appropriate use of drug testing in clinical addiction medicine, 2017 consensus document